Loading patent…
AssigneesInstitut Curie, Institut National de la Sante et de la Recherche Medicale
InventorsRaphaël CECCALDI, Marie VALLETTE, Marton KOVACS
Estimating the term…
The invention relates to methods and pharmaceutical compositions for the treatment of HRD cancer, particularly BRCA-associated cancer and chemo-resistance BRCA-associated cancer. The inventors investigated the role of VPS4B in HRD cancer, particularly in BRCA-associated cancer. The inventors demonstrated that HR-deficient cells have NE vulnerability, increased NE rupture and are sensitive to inhibitor of NE repair factors. The inventors also demonstrated that VPS4B is synthetic lethal in BRCA1/2-mutated cells and indicate that BRCA2−/− cells were extremely sensitive to VPS4B inhibition. Altogether, the present invention highlights the role of nuclear envelope (NE) repair factors, particularly VPS4B inhibitors in HRD cancer and the use of VPS4B inhibitors in the treatment of HRD cancer, particularly BRCA-associated cancer and BRCA-associated cancer with acquired drug resistance. Thus, the present invention relates to VPS4B inhibitor for use in the treatment of HRD cancer, particularly BRCA-associated cancer and chemo-resistance BRCA-associated cancer.
A method of treating HRD cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a VPS4B inhibitor.
A method of treating HRD cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a VPS4B inhibitor and a pharmaceutical acceptable carrier.
(canceled)
Dependencies are inferred from the claim text.